Join us in celebrating our 50th anniversary.
Join us in celebrating our 50th anniversary.

AST Newsletter Archives

The CLSI AST Outreach Working Group (ORWG) is part of the CLSI Subcommittee on Antimicrobial Susceptibility Testing (AST) and was established in 2015. The formation of the working group originated in a desire to efficiently convey information regarding contemporary AST practices, recommendations, and resources to the clinical microbiology community.

Sign-up For the AST News Update E-mails

Archived Newsletters:

  • Volume 1, Issue 1 Spring 2016
    • About CLSI AST ORWG
    • CLSI AST Subcommittee and Meetings
    • Availability of CLSI AST Subcommittee Materials
    • Recently Published CLSI AST Documents
    • Educational Materials for Carbapenem-resistant Enterobacteriaceae (CRE)
  • Volume 1, Issue 2 Winter 2016
    • Do You Need Help With Verification of Your AST System?
    • Special Considerations for Susceptibility Testing of Streptococcus agalactiae (Group B Streptococcus)
    • Continuing Conversation About Colistin!
    • The CLSI Anaerobe Working Group and Anaerobe Susceptibility Testing
    • Resistance Hot Topic! Vancomycin-Variable Enterococci:
      An Unrecognized Threat?
  • Volume 2, Issue 1 Spring 2017 (English)
    • The One Health Initiative
    • What is the Antibiotic Resistance Laboratory Network (ARLN)
    • A New Phenotypic Test for Detection of Carbapenemases – The Modified Carbapenem Inactivation Method (mCIM)
    • Carbapenems and Enterobacteriaceae: What is the difference between CRE vs Carbapenemase-Producing (CP)-CRE vs nonCP-CRE?
    • Newer Developments in Antifungal Susceptibility Testing - Species-Specific Breakpoints for Candida spp.
    • The 21st Century Cures Act and the Future of AST
    • Hot Topic – OXA Carbapenemases
    • In Memoriam – Dr. Paul Schreckenberger
  • Boletín de AST noticias de Junio 2017 (Español) 
    • La iniciativa One Health
    • ¿Que es la Antibiotic Resistance Laboratory Network (ARLN)?
    • Un nuevo test fenotípico para la detección de Carbapenemasas - The Modified Carbapenem Inactivation Method (mCIM)
    • Carbapenems y Enterobacteriaceae: Cual es la diferencia entre CRE vs productores de carbapanemasa (CP)- ¿CRE vs no-CP-CRE?
    • Nuevos desarrollos en pruebas de susceptibilidad antifúngica – Puntos de corte específicos para especies de Candida spp.
    • 10 El acta de curas para el sigo 21 y el futuro de AST
    • Tema Candente – Carbapenemasas OXA
    • En memoria – Dr. Paul Schreckenberger
  • Volume 3, Issue 1 Winter 2018 (English)
    • 21st Century Cures Act: Exciting News
    • Feature Article: Understanding Pharmacokinetics (PK) and Pharmacodynamics (PD)
    • Case Study: Direct Detection of MRSA/MSSA from Positive Blood Cultures
    • Burning Question: When Should Clinical Microbiology Laboratories Perform Carbapenemase Detection Tests
    • Article: Respiratory Illnesses and the Need for Antibiotic Stewardship
    • Article: Antimicrobial Susceptibility Testing of Bacteria Associated with Community-Acquired Pneumonia
    • Hot Topic: Candida auris
  • Volume 3, Issue 1 Winter 2018 (Chinese)
    • 21世纪治愈法案(The 21st Century Cures Act)——令人振奋的新闻
    • 专题文章:理解药代动力学(PK)和药效学 (PD)
    • 病例研究:血培养阳性样本直接检测 MRSA/MSSA
    • 最关注的问题:临床实验室应该何时进行 碳青霉烯酶检测试验?
    • 呼吸系统疾病和抗生素管理的需求
    • 社区获得性肺炎相关细菌的抗微生物药物 敏感试验
    • 热点话题——耳念珠菌
  • Volume 3, Issue 2 Spring 2018 (English)
    • Featured Article: Part 1 New β-lactam combination agents for the treatment of Gram-negative bacterial infections: what the clinical microbiologist needs to know!
    • Featured Article: Part 2 Why all the fuss over quality control of β-lactam combination agents?
    • Case Study: Cefazolin, Urine, and Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis: Entertaining Solutions for Antimicrobial Susceptibility Testing and Reporting
    • Burning Question: What Should Clinical Laboratorians Know About Gonorrhea in 2018?
    • Hot Topic: It’s Enough to mec You Crazy!